- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03166540
Bioavailability and Beneficial Properties of Coffee and Cocoa Bioactive Compounds (P4L)
Bioavailability and Beneficial Properties of Espresso Coffee and Confectionery Derived Coffee Bioactive Compounds
The aim of this study will be to define the bioavailability and the beneficial properties of coffee bioactive compounds. Moreover, the contribution of cocoa-based products containing coffee to the pool of circulating metabolites will be investigated with the aim of evaluating the effect of the combination of bioactives from different sources.
To study the bioavailability of coffee/cocoa bioactive compounds and their effects in cardiometabolic health, the objectives will be:
i) Assessing the bioavailability of the four main groups of phytochemicals in roasted coffee (methylxanthines, phenolic compounds, trigonelline, and diterpenes), its modulation by the level of consumption, and establishing the daily average concentration of coffee-derived plasma circulating metabolites; ii) Investigating the effect of different levels of coffee consumption on cardiometabolic risk factors; iii) Evaluating circulating metabolites and their putative bioactivity when substituting coffee consumption with the intake of cocoa-based products containing coffee.
A 3-arm, crossover, randomized trial will be conducted. Twenty-one volunteers will be randomly assigned to consume three treatments in a random order for 1 month: 1 cup of espresso coffee/day, 3 cups of espresso coffee/day, 1 cup of espresso coffee at breakfast and 2 cocoa-based products containing coffee two times per day. The last day of the treatment subjects will refer to the ambulatory where blood and urine samples will be collected at specific time points up to 24 hours following the consumption of the testing coffee or of the cocoa-based products containing coffee. In addition to the bioavailability of the bioactive compounds, the effect of the coffee consumption on several cardiometabolic risk factors (blood pressure, anthropometric measures, inflammatory markers, nitric oxide, blood lipids, fasting indices of glucose/insulin metabolism, DNA damage, eicosanoids, nutri-metabolomics) will be investigated. At the end of the treatment, the same protocol will be repeated, switching the allocation group.
Study Overview
Status
Intervention / Treatment
Detailed Description
A human bioavailability study will be carried out to achieve the above-described goals. The human intervention study will consist of a short-term randomized cross-over trial, addressed at measuring the daily mean concentrations of each coffee/cocoa-derived circulating metabolite (CCDCM) for the four main groups of coffee/cocoa phytochemicals (methylxanthines, trigonelline, phenolics, diterpenes). On the basis of different patterns of consumption, this free-living study (although some minimal dietary restrictions will be provided two days before sampling times) will also take into consideration the effects of repeated doses on the bioavailability of coffee/cocoa bioactives.
The study will follow a repeat-dose, 3-arm, cross-over design. This design has been chosen according to ILSI's guidelines for intervention trials with dietary products.
Subjects were assigned to consume the following treatments in a random order for 1 month:
- 1 cup of espresso coffee/day ("low consumers") at 9.00 A.M.
- 3 cups of espresso coffee/day ("high consumers") at 9.00 A.M., 12.00 P.M.noon and 3.00 P.M.
- 1 cup of espresso coffee at breakfast 9.00 A.M. and 2 cocoa-based products containing coffee two times per day (at 12.00 P.M.noon and 3.00 P.M.). The group will be named "medium consumers", considering the caffeine content of the cocoa-based products containing coffee.
Minimal recommendations to avoid other sources of coffee/cocoa phytochemicals besides what introduced through the assigned treatment, and to standardise the time of coffee consumption, will be provided for the two days prior to each sampling day and on the sampling day. Dinner timing and composition will also be standardised the day before the sampling day. Only water could be drunk during the night. At the sampling day (i.e. the last day of each intervention period), the subjects will refer in the morning at the ambulatory where fasting baseline blood and urine samples will be collected. Then, low and high consumers will drink one or three cups of espresso coffee, respectively (without sugar, sweeteners, and milk for the first coffee; with 5 g of sugar for the last two coffees), while medium consumers will drink a cup of espresso coffee and 2 cocoa-based products containing coffee twice during the day, following the above-described timing. After ingestion of the first coffee together with a phytochemical-free breakfast (a pastry), blood and urine samples will be collected at selected time points along the following 24-h. Five hours after the consumption of the first coffee, participants will receive a standardised mixed meal (sandwich with ham and cheese) free of coffee/cocoa phytochemical-related compounds. Water will be available ad libitum. Twenty-four hours after receiving the treatment, blood and urine samples will also be taken in order to assess return to baseline. In addition, anthropometric characteristics and blood pressure (BP) will be measured.
Socio-demographic variables will be assessed through a generic questionnaire filled at recruitment. The questionnaire will also contain questions useful to identify possible exclusion criteria (e.g. diagnosis for diseases, regular consumption of medication, food allergy). Dietary habits of volunteers will also be evaluated during the enrollment, through a semi-quantitative food frequency questionnaire (FFQ) for the assessment of dietary total antioxidant capacity. In addition, participants' food intakes and compliance with the study requirements will be assessed by means of 3-day dietary records, administered throughout each intervention period at two time points: i) in the middle of each intervention period during two weekdays and a weekend day, and ii) at the end of each intervention period, 2 days prior to the sampling day and the sampling day. The habitual physical activity level of each participant will be measured through a validated International Physical Activity Questionnaires.
Blood sample collection will be carried out in the ambulatory unit of the Department of Medicine and Surgery. Blood collection will be carried out by a physician. A venous catheter will be inserted into the antecubital vein and blood samples from each subject will be collected in specific tubes over 24 hours. Blood sampling at time-point 24h after first coffee consumption will be done by venipuncture. Urine samples will be collected during different periods of time using urine collectors.
Blood samples will be centrifuged and plasma, serum and peripheral blood mononuclear cells (PBMCs) will be collected, aliquoted, and stored at -80 °C for further processing. Urine samples will be aliquoted and stored at -80°C for further processing.
The primary selected endpoint of the study is the quantification of the daily mean concentration of coffee-derived plasma circulating phenolic metabolites, whereas the study of the bioavailability of other coffee-derived circulating bioactives, the bioavailability of cocoa-derived circulating phytochemicals, and the assessment of cardiometabolic markers will be considered secondary endpoints.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Parma, Italy, 43125
- Department of Food and Drug, University of Parma
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- adult
- both genders
- healthy
- normal weight (BMI 18-25)
- regular coffee consumers of 1-5 cups per day
Exclusion Criteria:
- younger than 18 y.o. or older than 60 y.o.
- clinically diagnosis for metabolic, renal or digestive disorders
- regular consumption of medication
- antibiotic therapy taken within the last 3 months
- intense physical activity
- pregnancy or lactation
- underweight or overweight/obese
- no regular consumption of coffee or regular intake exceeding 5 coffees/day
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: low consumers
1 cup of espresso coffee/day at 9.00 A.M. for 1 month
|
Subjects will consume the assigned treatment for one month.
Espresso coffee will be prepared by using coffee capsules.
Serving size: approximately 45 mL.
The last day of the intervention is the sampling day.
|
EXPERIMENTAL: high consumers
3 cup of espresso coffee/day at 9.00 A.M. 12.00 P.M. and 3.00 P.M. for 1 month
|
Subjects will consume the assigned treatment for one month.
Espresso coffee will be prepared by using coffee capsules.
Serving size: approximately 45 mL.
The last day of the intervention is the sampling day.
|
EXPERIMENTAL: medium consumers
1 cup of espresso coffee at 9.00 A.M. + cocoa-based products containing coffee at 12.00 P.M. and 3.00 P.M. for 1 month
|
Subjects will consume the assigned treatment for one month.
Espresso coffee will be prepared by using coffee capsules.
Serving size: approximately 45 mL.
The last day of the intervention is the sampling day.
Subjects will consume the assigned treatment (2 products per serving) for one month.
Serving size: approximately 37 g.
The last day of the intervention is the sampling day.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Daily mean concentration of phenolic metabolites
Time Frame: 24 hours (0 -overnight fasting-, 30, 60, 120, 180, 240, 300, 360, 420, 480, 540, 1440 -overnight fasting- minutes)
|
Assessment of the daily mean concentration of coffee derived plasma circulating phenolic metabolites
|
24 hours (0 -overnight fasting-, 30, 60, 120, 180, 240, 300, 360, 420, 480, 540, 1440 -overnight fasting- minutes)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Coffee-derived plasma circulating bioactives
Time Frame: 24 hours (0 -overnight fasting-, 30, 60, 120, 180, 240, 300, 360, 420, 480, 540, 1440 -overnight fasting- minutes)
|
Profile of metabolites coming from coffee phytochemicals (phenolic compounds, trigonelline, caffeine, and diterpenes) in plasma
|
24 hours (0 -overnight fasting-, 30, 60, 120, 180, 240, 300, 360, 420, 480, 540, 1440 -overnight fasting- minutes)
|
Coffee-derived bioactives in urine
Time Frame: 24 hours (0 -overnight fasting-, 180, 360, 540, 1440 -overnight fasting- minutes)
|
Profile of metabolites coming from coffee phytochemicals (phenolic compounds, trigonelline, caffeine, and diterpenes) in urine
|
24 hours (0 -overnight fasting-, 180, 360, 540, 1440 -overnight fasting- minutes)
|
Cocoa-derived plasma circulating bioactives
Time Frame: 24 hours (0 -overnight fasting-, 30, 60, 120, 180, 240, 300, 360, 420, 480, 540, 1440 -overnight fasting- minutes)
|
Profile of metabolites coming from cocoa phytochemicals (phenolic compounds and theobromine) in plasma
|
24 hours (0 -overnight fasting-, 30, 60, 120, 180, 240, 300, 360, 420, 480, 540, 1440 -overnight fasting- minutes)
|
Cocoa-derived bioactives in urine
Time Frame: 24 hours (0 -overnight fasting-, 180, 360, 540, 1440 -overnight fasting- minutes)
|
Profile of metabolites coming from cocoa phytochemicals (phenolic compounds and theobromine) in urine
|
24 hours (0 -overnight fasting-, 180, 360, 540, 1440 -overnight fasting- minutes)
|
Blood Pressure
Time Frame: two time (0 -overnight fasting-, 1 month-fasting-)
|
Systolic and diastolic blood pressure
|
two time (0 -overnight fasting-, 1 month-fasting-)
|
Body Mass Index (BMI)
Time Frame: two time (0 -overnight fasting-, 1 month-fasting-)
|
Weight (in kg) and height (in m) will be combined to report BMI in kg/m2
|
two time (0 -overnight fasting-, 1 month-fasting-)
|
Waist circumference
Time Frame: two time (0 -overnight fasting-, 1 month-fasting-)
|
two time (0 -overnight fasting-, 1 month-fasting-)
|
|
Trimethyl-ammine-N-oxide (TMAO) in plasma
Time Frame: 24 hours (0 -overnight fasting-, 30, 60, 120, 180, 240, 300, 360, 420, 480, 540, 1440 -overnight fasting- minutes)
|
24 hours (0 -overnight fasting-, 30, 60, 120, 180, 240, 300, 360, 420, 480, 540, 1440 -overnight fasting- minutes)
|
|
Trimethyl-ammine-N-oxide (TMAO) in urine
Time Frame: 24 hours (0 -overnight fasting-, 180, 360, 540, 1440 -overnight fasting- minutes)
|
24 hours (0 -overnight fasting-, 180, 360, 540, 1440 -overnight fasting- minutes)
|
|
Nitric oxide (NO) in plasma
Time Frame: 1440 -overnight fasting- minutes
|
1440 -overnight fasting- minutes
|
|
Blood lipids
Time Frame: 1440 -overnight fasting- minutes
|
Total cholesterol, HDL, LDL, triglycerides
|
1440 -overnight fasting- minutes
|
Glucose and Insulin
Time Frame: 1440 -overnight fasting- minutes
|
Fasting glucose and fasting insulin
|
1440 -overnight fasting- minutes
|
DNA damage
Time Frame: 24 hours (0 -overnight fasting-, 60, 240, 420, 1440 -overnight fasting- minutes)
|
Assessed by using the Comet assay
|
24 hours (0 -overnight fasting-, 60, 240, 420, 1440 -overnight fasting- minutes)
|
DNA catabolites
Time Frame: 24 hours (0 -overnight fasting-, 60, 240, 420, 1440 -overnight fasting- minutes)
|
Assessed by using LC-MS for individual detection and quantification
|
24 hours (0 -overnight fasting-, 60, 240, 420, 1440 -overnight fasting- minutes)
|
Nutri-metabolomics in plasma
Time Frame: 1440 -overnight fasting- minutes
|
Metabolomics will be carried out in fasting plasma to unravel the potential metabolic pathways of molecules present in the food matrix
|
1440 -overnight fasting- minutes
|
Nutri-metabolomics in urine
Time Frame: 24 hours (0 -overnight fasting-, 180, 360, 540, 1440 -overnight fasting- minutes)
|
Metabolomics will be carried out in urine to unravel the potential metabolic pathways of molecules present in the food matrix
|
24 hours (0 -overnight fasting-, 180, 360, 540, 1440 -overnight fasting- minutes)
|
Eicosanoids in urine
Time Frame: 24 hours (0 -overnight fasting-, 180, 360, 540, 1440 -overnight fasting- minutes)
|
24 hours (0 -overnight fasting-, 180, 360, 540, 1440 -overnight fasting- minutes)
|
|
Inflammatory markers in plasma
Time Frame: 1440 -overnight fasting- minutes
|
Main inflammatory markers associated with coffee consumption
|
1440 -overnight fasting- minutes
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Daniele Del Rio, Ph.D., University of Parma
- Study Director: Pedro M Mena Parreño, Ph.D., University of Parma
Publications and helpful links
General Publications
- Mena P, Bresciani L, Tassotti M, Rosi A, Martini D, Antonini M, Cas AD, Bonadonna R, Brighenti F, Del Rio D. Effect of different patterns of consumption of coffee and a cocoa-based product containing coffee on the nutrikinetics and urinary excretion of phenolic compounds. Am J Clin Nutr. 2021 Dec 1;114(6):2107-2118. doi: 10.1093/ajcn/nqab299.
- Martini D, Rosi A, Tassotti M, Antonini M, Dall'Asta M, Bresciani L, Fantuzzi F, Spigoni V, Dominguez-Perles R, Angelino D, Ricci C, Del Pozo-Luengo S, Tornel PL, Scazzina F, Gil-Izquierdo A, Dei Cas A, Brighenti F, Bonadonna R, Del Rio D, Mena P. Effect of coffee and cocoa-based confectionery containing coffee on markers of cardiometabolic health: results from the pocket-4-life project. Eur J Nutr. 2021 Apr;60(3):1453-1463. doi: 10.1007/s00394-020-02347-5. Epub 2020 Jul 29.
- Mena P, Tassotti M, Martini D, Rosi A, Brighenti F, Del Rio D. The Pocket-4-Life project, bioavailability and beneficial properties of the bioactive compounds of espresso coffee and cocoa-based confectionery containing coffee: study protocol for a randomized cross-over trial. Trials. 2017 Nov 9;18(1):527. doi: 10.1186/s13063-017-2271-2.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DDR-P4L
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diet Modification
-
University of Rhode IslandCompletedDiet Modification | Diet HabitUnited States
-
University of ReadingActive, not recruitingDiet Modification | Diet, Healthy | Diet HabitUnited Kingdom
-
University of Rhode IslandBrown University; University of ConnecticutCompletedDiet ModificationUnited States
-
Purdue UniversityCompletedDiet ModificationUnited States
-
Quadram Institute BioscienceNorfolk and Norwich University Hospitals NHS Foundation TrustCompleted
-
Loma Linda UniversityArdmore Institute of HealthCompleted
-
University Hospital Southampton NHS Foundation...Medical Research Council; University of SouthamptonCompleted
-
University Hospital Southampton NHS Foundation...Medical Research Council; University of Southampton; National Institute for Health... and other collaboratorsActive, not recruitingDiet ModificationUnited Kingdom
Clinical Trials on cup of espresso coffee
-
Heidelberg UniversityCompleted
-
Agricultural University of AthensNestléCompletedSigns and Symptoms, Digestive | Stress | Blood Pressure | Increased Secretion of Gastrin
-
University of ArkansasCompleted
-
University of LausanneNestlé Research Center, Vers-chez-les-blanc, SwitzerlandCompletedHepatic SteatosisSwitzerland
-
University of CopenhagenCompleted
-
Liverpool School of Tropical MedicineCenters for Disease Control and Prevention; Kenya Medical Research Institute; Safe Water and AIDS Project (SWAP), KenyaCompletedHIV Infections | Quality of Life | Adolescent Behavior | Reproductive Health | Herpesvirus Infection | Woman AbuseKenya
-
West Park Healthcare CentreCompletedCystic Fibrosis in ChildrenCanada
-
Rajavithi HospitalCompletedEffects of Coffee Ingestion on Recovery of Bowel FunctionThailand
-
Azienda Ospedaliera Universitaria Integrata VeronaUnknownPostoperative Complications | Pancreatic Diseases | Postoperative Ileus | Bowel DysfunctionItaly